Pemirolast Potassium

CHEMBL1201050 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

266.3 g/mol

LogP

—

Phase

4

A potassium salt form of pemirolast, sharing the same therapeutic uses.

分子量

266.3000 g/mol

TPSA

72.30 Å²

治療領域

Asthma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1cccn2c(=O)c(-c3nnn[n-]3)cnc12.[K+]

InChI

InChI=1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1

Molecular Formula

C10H7KN6O

HBD / HBA

- / 6

回転可能結合数

1

重原子数

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A potassium salt form of pemirolast, sharing the same therapeutic uses.

Yes, Pemirolast Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201050. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 443866. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Pemirolast Potassium PillFYIで

構造

クイックデータ

分子式: C10H7KN6O

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.